ImClone, Immunex deal

The companies cross-licensed technology relating to FLT-3/FLK-2 ligand and its receptor. The ligand is a hematopoietic growth factor that

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE